Publication:
Evaluation of time in therapeutic range among patients receiving warfarin therapy: A retrospective cohort study at one private hospital in Thailand

dc.contributor.authorFeungfu L.
dc.contributor.authorRaksasilp T.
dc.contributor.authorSwaengsak N.
dc.contributor.authorChysirichote T.
dc.contributor.authorSantiyanon N.
dc.contributor.authorYeephu S.
dc.date.accessioned2022-03-10T13:17:20Z
dc.date.available2022-03-10T13:17:20Z
dc.date.issued2021
dc.date.issuedBE2564
dc.description.abstractThe quality of warfarin therapy is often measured by the percentage oftime that a patient spends within target international normalized ratio (INR) range (time in therapeutic range, TTR). It has been found that TTR can strongly predict both bleeding and thromboembolic events. This retrospective cohort study was conducted to evaluate the meanTTR and the predictors ofinadequate anticoagulation control among subjects attending the warfarin clinic at one private hospital in Thailand during June 2012 and May 2016. Study subjects consisted of patients who had been taking warfarin for all indications with target INR 2.0-3.0. TTR was calculated through the Rosendaal method which provides the percentage of days when INR values are in desired range. A total of 196 patients (71.9% female, mean age 69.55 years) recruited represented the average TTR value of 60.46%. The stratification of patients according to anticoagulant control levels indicated that the poor control group (TTR < 65%) and the good control group (TTR ≥ 65%) contained 103 patients (52.55%) and 93 patients (47.45%), respectively. The mean TTR value of the poor control group was significantly lower than the good control group (43.64% vs. 79.09%; P < 0.001). It was found that comorbid heart failure, history of non-adherence, warfarin-drug interaction and warfarin-food/herb interaction were associated with the status of poor anticoagulant control (adjusted OR were 7.258, 18.232, 2.886 and 5.828, respectively). Recognition of these predictive factors could be beneficial in improving pharmaceutical care activities in order to optimize TTR value among patients receiving warfarin therapy. © 2021. Faculty of Pharmacy, Mahidol University (Thailand).
dc.format.mimetypeapplication/pdf
dc.identifier.citationPharmaceutical Sciences Asia. Vol 48, No.2 (2021), p.107-114
dc.identifier.doi10.29090/psa.2021.02.19.143
dc.identifier.issn25868195
dc.identifier.other2-s2.0-85102523569
dc.identifier.urihttps://hdl.handle.net/20.500.14740/8091
dc.language.isoeng
dc.rights.holderScopus
dc.subject.otherWarfarin
dc.subject.otherAdult
dc.subject.otherAged
dc.subject.otherAlcohol consumption
dc.subject.otherAnticoagulant therapy
dc.subject.otherAnticoagulation
dc.subject.otherArticle
dc.subject.otherAtherosclerosis
dc.subject.otherAtrial fibrillation
dc.subject.otherBleeding
dc.subject.otherCerebrovascular accident
dc.subject.otherCohort analysis
dc.subject.otherComorbidity
dc.subject.otherControlled study
dc.subject.otherDeep vein thrombosis
dc.subject.otherDrug indication
dc.subject.otherFemale
dc.subject.otherFood drug interaction
dc.subject.otherHeart failure
dc.subject.otherHerb drug interaction
dc.subject.otherHuman
dc.subject.otherInternational normalized ratio
dc.subject.otherLung embolism
dc.subject.otherMajor clinical study
dc.subject.otherMale
dc.subject.otherMedical history
dc.subject.otherPatient compliance
dc.subject.otherPharmaceutical care
dc.subject.otherPrivate hospital
dc.subject.otherRetrospective study
dc.subject.otherSmoking
dc.subject.otherThailand
dc.subject.otherThyroid disease
dc.subject.otherTime in therapeutic range
dc.subject.otherTreatment refusal
dc.subject.otherTreatment response time
dc.titleEvaluation of time in therapeutic range among patients receiving warfarin therapy: A retrospective cohort study at one private hospital in Thailand
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85102523569&doi=10.29090%2fpsa.2021.02.19.143&partnerID=40&md5=42ca0007ae92ae164386221b21b4cca8

Files